Says OMICRON has growth advantage
Admin l Tuesday, November 30, 2021
LAGOS, Nigeria – The World Health Organisation, WHO has said that the Coronavirus variant, which has been named OMICRON variant has been increasing across almost all province in South Africa.
WHO raised the concern as the variant continues to spread abroad. The B.1.1.529 variant(OMICRON) was first reported to WHO from South Africa on 24 November 2021.
According to the Technical Advisory Group on SARS-CoV-2 Virus Evolution, the epidemiological situation in South Africa has been characterized by three distinct peaks in reported cases, the latest of which was predominantly the Delta variant.
It added that in recent weeks, infections have increased steeply, coinciding with the detection of B.1.1.529 variant, stressing that the first known confirmed B.1.1.529 infection was from a specimen collected on 9 November 2021.
This OMICRON variant according to WHO has a large number of mutations, some of which are source of concern. It added that preliminary evidence suggests an increased risk of reinfection with this variant, as compared to other VOCs.
“ Several labs have indicated that for one widely used PCR test, one of the three target genes is not detected (called S gene dropout or S gene target failure) and this test can therefore be used as marker for this variant, pending sequencing confirmation. Using this approach, this variant has been detected at faster rates than previous surges in infection, suggesting that this variant may have a growth advantage”, it added.
WHO said there are a number of studies underway and the TAG-VE will continue to evaluate this variant. WHO will communicate new findings with Member States and to the public as needed.
“Based on the evidence presented indicative of a detrimental change in COVID-19 epidemiology, the TAG-VE has advised WHO that this variant should be designated as a VOC, and the WHO has designated B.1.1.529 as a VOC, named Omicron”, WHO said.
Based on this variant, WHO has urged , countries to enhance surveillance and sequencing efforts to better understand circulating SARS-CoV-2 variants, submit complete genome sequences and associated metadata to a publicly available database, such as GISAID, report initial cases/clusters associated with VOC infection to WHO through the IHR mechanism.
It noted that where capacity exists and in coordination with the international community, perform field investigations and laboratory assessments to improve understanding of the potential impacts of the VOC on COVID-19 epidemiology, severity, effectiveness of public health and social measures, diagnostic methods, immune responses, antibody neutralization, or other relevant characteristics.
It advised individuals to take measures to reduce their risk of COVID-19, including proven public health and social measures such as wearing well-fitting masks, hand hygiene, physical distancing, improving ventilation of indoor spaces, avoiding crowded spaces, and getting vaccinated.
